Which companies are Jiangsu Sihuan Bioengineering's closest peers?

The cockpit's peer set: Hainan Shuangcheng Pharmaceuticals (002693.SZ), Pulike Biological Engineering (603566.SS), Elixiron Immunotherapeutics (Cayman) (7871.TWO), CytomX Therapeutics (CTMX), YungShin Global (3705.TW), Cachet Pharmaceutical (002462.SZ), Kexing Biopharm (688136.SS), Zhejiang Huakang Pharmaceutical (605077.SS).

Is Jiangsu Sihuan Bioengineering expensive compared with its peers?

On ev / sales it trades at 11.5× against a peer median of 3.3×, 3rd most expensive of 21 in its peer set.

How has Jiangsu Sihuan Bioengineering stock performed?

Over six months to 6 Nov 2026 the shares returned +6.9% against -20.6% for the median peer; over one year +23.7%.

← CockpitCompetitor Analysis › 000518.SZ Jiangsu Sihuan Bioengineering Co., Ltd. Class AOpen in the cockpit ↗

Jiangsu Sihuan Bioengineering Co., Ltd. Class A000518.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Momentum neutral 59

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$476M

US dollars, full cap

Free float

69%

of shares outstanding

$/day

$13.0M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-17.7 pp

WACC 5.4%

Hurdle

n/a

no reverse DCF

Close · CNYCN¥3.08

1D-2.5%

1W0.0%

1M-15.4%

3M-16.5%

6M+6.9%

YTD+27.8%

1Y+23.7%

ATR %4.8%

52w lowhigh32.2% off high

What Jiangsu Sihuan Bioengineering does

Employees: 232

Jiangsu Sihuan Bioengineering at a glance

Size Jiangsu Sihuan Bioengineering (000518.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $476M, the 3972nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥3.08 on 6 Nov 2026.

Performance Over six months the shares gained 6.9%, against -20.6% for the median peer and -16.4% for the China market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue fell 17.0% over the last twelve months (peer median -4.9%); the operating margin is -28.5% (peer median 4.3%).

Valuation It trades at 11.5× enterprise value to sales against a peer median of 3.3× (3rd most expensive of 21).

Capital Return on invested capital runs 17.7 points below its cost of capital (5.4% WACC).

Relative performance

Six months, rebased to 100: Jiangsu Sihuan Bioengineering against the median of its 20 peers (local-currency closes).

Jiangsu Sihuan Bioengineering financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥284M	CN¥344M	CN¥203M	CN¥235M	CN¥269M
Revenue growth	—	+69%	-14%	-13%	—
Gross profit	CN¥61.5M	CN¥124M	CN¥119M	CN¥152M	CN¥180M
EBITDA	n/a	-CN¥29.5M	-CN¥51.6M	-CN¥50.6M	-CN¥30.9M
Net income	-CN¥72.9M	-CN¥37.1M	-CN¥110M	-CN¥75.3M	-CN¥48.8M
Free cash flow	-CN¥36.1M	CN¥74.5M	-CN¥4.10M	-CN¥6.55M	-CN¥3.61M
Capital expenditure	CN¥6.01M	CN¥3.60M	CN¥5.56M	CN¥8.19M	CN¥8.47M
Total debt	CN¥149M	CN¥33.9M	CN¥39.8M	CN¥47.9M	CN¥48.7M

Quarterly statements and history in the cockpit →

Jiangsu Sihuan Bioengineering competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Jiangsu Sihuan Bioengineering is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiangsu Sihuan Bioengineering is the large dot.

Jiangsu Sihuan Bioengineering competitors and peer comparison

How Jiangsu Sihuan Bioengineering compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiangsu Sihuan Bioengineering against its 20 peers (data as of 6 Nov 2026)
Measure	000518.SZ	Peer median	Rank in peer set
1-month return	-15.4%	-11.3%	6th lowest of 20
6-month return	+6.9%	-20.6%	4th highest of 20
Distance from 52-week high	-32.2%	-40.7%	5th highest of 20
Revenue growth (TTM)	-17.0%	-4.9%	4th lowest of 21
Operating margin	-28.5%	4.3%	6th lowest of 21
EV / Sales	11.5×	3.3×	3rd most expensive of 21
ROIC minus cost of capital	-17.7 pp	-2.1 pp	3rd lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Jiangsu Sihuan Bioengineering 000518.SZ	China	$476M	+7%	-17%	-28%	11.5×	n/a	n/a
Hainan Shuangcheng Pharmaceuticals 002693.SZ	China	$476M	-10%	+40%	13%	11.1×	44.5%	+1.0%
Pulike Biological Engineering 603566.SS	China	$475M	-22%	-9%	5%	2.5×	5.7%	+3.3%
Elixiron Immunotherapeutics (Cayman) 7871.TWO	Taiwan	$477M	+62%	+10,947%	-194%	132.2×	n/a	n/a
CytomX Therapeutics CTMX	United States	$477M	-45%	-87%	-477%	8.3×	n/a	n/a
YungShin Global 3705.TW	Taiwan	$474M	+7%	-8%	15%	1.9×	-4.9%	+0.7%
Cachet Pharmaceutical 002462.SZ	China	$471M	-22%	-14%	0%	0.2×	-8.9%	-3.4%
Kexing Biopharm 688136.SS	China	$470M	-38%	-14%	-12%	3.1×	n/a	n/a
Zhejiang Huakang Pharmaceutical 605077.SS	China	$470M	-39%	+35%	4%	1.2×	n/a	n/a
Alpha Teknova TKNO	United States	$482M	+104%	+12%	-35%	11.3×	n/a	n/a
Shanghai Shenqi Pharmaceutical Investment Management 600613.SS	China	$483M	+9%	-4%	3%	1.4×	13.4%	+1.4%
Tong Ren Tang Technologies 1666.HK	Hong Kong	$484M	-23%	-14%	12%	0.5×	-18.6%	+6.3%
Harbin Medisan Pharmaceutical 002900.SZ	China	$467M	-13%	-5%	-29%	4.5×	n/a	n/a
Daewoong 003090.KS	South Korea	$485M	-29%	+5%	11%	0.9×	n/a	n/a
Evonile Pharma EVONILE.NS	India	$466M	n/a	-5%	12%	14.5×	46.5%	-1.5%
Shaanxi Kanghui Pharmaceutical Co 603139.SS	China	$466M	-20%	-21%	-68%	9.0×	n/a	n/a
Teyi Pharmaceutical 002728.SZ	China	$465M	-9%	-7%	7%	3.5×	26.6%	+8.0%
Shanghai Jiaoda Onlly 600530.SS	China	$464M	-22%	-2%	-2%	10.4×	33.5%	-0.9%
Zhuhai Rundu Pharmaceutical 002923.SZ	China	$464M	-30%	+14%	5%	2.4×	2.5%	-1.3%
PKU Healthcare 000788.SZ	China	$489M	-11%	-49%	5%	2.5×	-2.6%	-5.6%
Zhejiang Chengyi Pharmaceutical 603811.SS	China	$463M	-21%	+7%	19%	3.6×	7.1%	+1.3%

Questions

Which companies are Jiangsu Sihuan Bioengineering's closest peers?: The cockpit's peer set: Hainan Shuangcheng Pharmaceuticals (002693.SZ), Pulike Biological Engineering (603566.SS), Elixiron Immunotherapeutics (Cayman) (7871.TWO), CytomX Therapeutics (CTMX), YungShin Global (3705.TW), Cachet Pharmaceutical (002462.SZ), Kexing Biopharm (688136.SS), Zhejiang Huakang Pharmaceutical (605077.SS).
Is Jiangsu Sihuan Bioengineering expensive compared with its peers?: On ev / sales it trades at 11.5× against a peer median of 3.3×, 3rd most expensive of 21 in its peer set.
How has Jiangsu Sihuan Bioengineering stock performed?: Over six months to 6 Nov 2026 the shares returned +6.9% against -20.6% for the median peer; over one year +23.7%.